Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA against c-Myc refers to a class of small interfering RNA molecules designed to silence the expression of the c-Myc (MYC) oncogene through the RNA interference (RNAi) pathway. c-Myc is a potent transcription factor that regulates a vast array of genes involved in cell proliferation, metabolism, and apoptosis, and its dysregulation is a hallmark of many human cancers. In research contexts, such as the study of radiation-induced cellular senescence, c-Myc siRNA is utilized to investigate the molecular mechanisms of oncogene-induced senescence (OIS) and bystander effects. By degrading c-Myc mRNA, these siRNAs prevent the translation of the c-Myc protein, thereby inhibiting its transcriptional activity and downstream biological effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on siRNA against c-Myc.